Irisin
The 'exercise hormone' whose existence in humans was contested for years. The story is more interesting than either side has admitted.
Investigational compounds — read carefully
This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.
Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.
At a glance
A peptide cleaved from the membrane protein FNDC5 and released by exercising skeletal muscle. The 2012 discovery generated enormous attention; the subsequent decade of debate over whether it actually exists in humans is one of the more instructive stories in modern peptide biology.
- Class
- FNDC5-derived myokine
- Sponsor
- Academic research programs (Spiegelman lab and others)
- Stage
- Preclinical / early translational
- Lead use case
- Exercise-mimetic, metabolic, neurological research
What it is
Irisin is a peptide cleaved from fibronectin type III domain-containing protein 5 (FNDC5), which is induced in skeletal muscle by exercise and other stresses. It was characterized in 2012 (Boström et al., Nature) as the molecular signal that converts white adipose tissue toward a brown-like phenotype and contributes to exercise-induced metabolic adaptations.
Current research status
Irisin remains primarily a research compound. The therapeutic development pathway has been complicated by methodological controversies that delayed but ultimately did not invalidate the field's interest.
Mechanistic rationale
FNDC5 is induced by PGC-1α — the same coactivator that drives exercise-induced mitochondrial biogenesis. After membrane cleavage, the soluble irisin peptide acts on αV integrin receptors in adipose tissue, bone, and brain to produce browning of white adipose tissue, increased thermogenesis, and (in animal models) cognitive and bone-density benefits.
Available evidence
Original characterization (Boström et al., Nature 2012) — Irisin identified as an exercise-induced myokine driving adipose browning in mice.[1]
The methodological controversy — Erickson 2013 and subsequent papers raised serious questions about the antibodies used to detect irisin in human studies and whether FNDC5 was actually cleaved and released in humans at biologically meaningful levels.
Resolution and continued work — Mass-spectrometry-based detection (Jedrychowski et al., 2015) confirmed that human FNDC5 is in fact cleaved and circulates, putting the existence question to rest. Subsequent work has focused on receptor identification (αV integrins) and downstream effects.[2]
Why it's interesting
Irisin is one of the cleanest examples of how scientific stories develop messily in real time. The 2012-2015 controversy was substantial — for several years the leading critique was that the molecule didn't really exist in humans. Mass-spec resolved that. The story since then has been the more conventional one: real biology, modest effect sizes in humans, complicated translation. The cognitive-aging effects in mouse studies are particularly interesting and align with the broader exercise-cognition connection.
Limitations & risks
Therapeutic-grade irisin development has been limited. Native irisin's short half-life and the engineering work required to produce a long-acting therapeutic candidate have been substantial. Whether the mouse-model effects (adipose browning, bone density, cognitive benefits) translate to humans at administered doses is the open question — and the same question that defines the broader exercise-mimetic field.
Community discussion notes
Discussed extensively in exercise-physiology and longevity communities, often as part of the broader 'exercise mimetic' conversation alongside SLU-PP-332 and AICAR. Grey-market 'irisin' products exist but are of uncertain identity given the molecular complexity and the field's own validation history.
The takeaway
Irisin is real. The question is whether administered irisin (or irisin analogs, or pathway agonists) translates to clinically meaningful effects in humans. This is the same question facing the broader exercise-mimetic field, and irisin's particular history — including the resolved methodological controversy — makes it a useful lens for thinking about how peptide hormones move from discovery to therapy.
References
- Boström P, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463-468. https://pubmed.ncbi.nlm.nih.gov/22237023/
- Jedrychowski MP, et al. Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. Cell Metab. 2015;22(4):734-740. https://pubmed.ncbi.nlm.nih.gov/26278050/